Tatva Chintan Pharma Chem Limited has issued an intimation to shareholders regarding the Tax Deduction at Source (TDS) on its final dividend for FY26, setting a strict deadline of September 10, 2026, for document submission. The Board of Directors, in a meeting held on May 16, 2026, recommended a final dividend of ₹2.00 per equity share (face value ₹10), representing a 20% payout. This dividend is subject to shareholder approval at the 30th Annual General Meeting (AGM). Under the Income-tax Act, 2025, dividend income is taxable in the hands of shareholders, requiring the company to deduct tax at source before payment.

The company has outlined specific TDS rates based on shareholder category and documentation status. For resident individual shareholders, no TDS will be deducted if the aggregate dividend payable during the tax year does not exceed ₹10,000. Other resident shareholders with valid PAN cards are subject to a 10% TDS rate. However, shareholders who fail to provide a valid PAN, have an unlinked PAN-Aadhaar combination, or are classified as specified persons under the income tax portal will face a higher TDS rate of 20% under Section 397(2)(b)(i) of the Act. Resident entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIFs) may claim NIL or lower withholding tax by submitting self-declarations and relevant registration documents.

Non-resident shareholders, including Foreign Institutional Investors (FIIs) and Foreign Portfolio Investors (FPIs), face a standard withholding tax rate of 20%, plus applicable surcharge and cess. To avail benefits under the Double Tax Avoidance Agreement (DTAA), non-residents must submit a Tax Residency Certificate (TRC), Form 41 via the income tax portal, and a self-declaration confirming no Permanent Establishment in India. The application of beneficial DTAA rates is contingent upon the completeness and satisfactory review of these documents by the company. In the absence of valid documentation, the standard higher rate will apply.

Key Compliance Deadlines and Requirements

Shareholders must update their records with their Depository Participants (for demat holdings) or the Registrar and Share Transfer Agent, MUFG Intime India Private Limited (for physical holdings). The following table summarizes the critical compliance actions:

The company emphasized that no communication regarding tax determination or deduction will be entertained after September 10, 2026. Shareholders holding shares under multiple accounts with a single PAN will be subject to the highest applicable TDS rate across all their holdings. Additionally, clearing members must ensure shares are transferred to respective shareholder accounts by the record date to facilitate direct dividend credit.

What the Numbers Show

The mandatory shift to shareholder-level taxation, enforced through strict TDS mechanisms, highlights the regulatory emphasis on compliance under the Income-tax Act, 2025. The imposition of a 20% penalty rate for non-compliance—specifically for unlinked PAN-Aadhaar details or missing documentation—serves as a significant deterrent against administrative lapses. For institutional investors, the requirement to file Form 41 digitally and provide TRCs adds a layer of procedural complexity that must be managed well before the payment date to avoid cash flow impacts from excess withholding.

Tatva Chintan Pharma Chem Limited will conduct a virtual one-to-one interaction with Mahindra Manulife Investment Management Private Limited on August 06, 2026. The company filed the intimation with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 03, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This engagement allows institutional investors to engage with management using only publicly available data, ensuring transparency and adherence to regulatory guidelines regarding unpublished price-sensitive information (UPSI).

Ishwar Ramanbhai Nayi, Company Secretary and Compliance Officer of Tatva Chintan Pharma, signed the submission confirming the schedule. The filing replaces an earlier intimation that listed a different participant, reflecting the final confirmed agenda for the upcoming session.

Meeting Details

The interaction is structured as a focused dialogue between the company's representatives and the selected financial institution. The session will be conducted virtually, ensuring accessibility without geographical constraints.

Regulatory Compliance and Information Scope

Management emphasized that the discussion will be confined to information already in the public domain. No confidential or unpublished price-sensitive information will be shared during the interaction, aligning with standard compliance protocols for such meetings. Any updates or changes to the schedule will be communicated promptly, with all relevant information made available on the company’s official website at www.tatvachintan.com .

What the Numbers Show

While this filing does not contain new financial metrics, the decision to host a dedicated one-to-one session with Mahindra Manulife Investment Management signals active investor relations efforts. By restricting the scope to publicly available information, the company reinforces its commitment to equal information access, preventing any selective disclosure advantages while keeping institutional investors updated on strategic directions already known to the market.